Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Chinese Patent Office
Federal Trade Commission
Cantor Fitzgerald

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,149,940

« Back to Dashboard

Which drugs does patent 6,149,940 protect, and when does it expire?

Patent 6,149,940 protects UROXATRAL and is included in one NDA. There has been one Paragraph IV challenge on Uroxatral.

Protection for UROXATRAL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-one patent family members in thirty-eight countries.

Summary for Patent: 6,149,940

Title: Tablet with controlled release of alfuzosine chlorhydrate
Abstract:Pharmaceutical tablet which consists of: a) a first layer having the property of swelling considerably and quickly on contact with aqueous biological fluids, the first layer being produced by compression of a mixture or of a granulate comprising hydrophilic polymers, and b) a second layer adjacent to the first layer being formulated with hydrophilic polymers and with other auxiliary substances in order to give the preparation suitable properties of compressibility and in order to allow the release of alfuzosin hydrochloride within a predetermined time period.
Inventor(s): Maggi; Lauretta (Pavia, IT), Conte; Ubaldo (Busto Arisizio., IT), Grenier; Pascal (Saint Louis, FR), Vergnault; Guy (Saint Louis, FR), Dufour; Alain (Paris, FR), Jarreau; Fran.cedilla.ois Xavier (Versailles, FR), Rauch-Desanti; Clemence (Ozoire la Ferriere, FR)
Assignee: Synthelabo (Le Plessis-Robinson, FR) Jagotec AB (Hergiswil, CH)
Application Number:09/147,581
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Concordia Pharms IncUROXATRALalfuzosin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021287-001Jun 12, 2003ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,149,940

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France96 10551Aug 29, 1996
France97 04386Apr 10, 1997
PCT Information
PCT FiledAugust 22, 1997PCT Application Number:PCT/FR97/01515
PCT Publication Date:March 05, 1998PCT Publication Number: WO98/08515

International Patent Family for Patent: 6,149,940

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
France2752737► Subscribe
Greece3036291► Subscribe
Hong Kong1020875► Subscribe
Hungary9903428► Subscribe
Spain2159400► Subscribe
European Patent Office0938318► Subscribe
Israel128146► Subscribe
Hungary228007► Subscribe
South Korea20000035929► Subscribe
Iceland4964► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Johnson and Johnson
Harvard Business School
Federal Trade Commission
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: